Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis

Introduction: Hypertension and dyslipidemia are common contributors to cardiovascular disease (CVD), often occurring together. Effectively Managing both is key to reducing mortality and morbidity, but complex regimens reduce adherence.

Aim: This study investigated the comparative efficacy and safety of a three-drug regimen (TAR) containing telmisartan, amlodipine, and rosuvastatin against two-drug combinations (TA and TR) for managing hypertension and dyslipidemia.

Methods: We searched PubMed, Web of Science, Cochrane, Embase, and Scopus databases for relevant articles matching our inclusion criteria. Following the application of inclusion criteria, four studies were selected for qualitative analysis and four studies for meta-analysis.

Results: Our analysis showed TAR [n = 155] significantly reduced mean systolic blood pressure (MSSBP) at week 4 compared to TR (n = 163) (MD = -15.65 mmHg) and TA (MD = -4.63 mmHg). TAR also showed superiority over all groups (TR [n = 163], TA [n = 162]) in MSSBP reduction. For low-density lipoprotein-cholesterol (LDL-C), TAR only showed a significant difference at week 4 compared to TA (MD = -86.41 mg/dL), with no difference between TAR and TR at either week 4 or 8.

Conclusion: Our findings suggest that TAR may be a safe and effective therapeutic option for the concurrent management of hypertension and dyslipidemia. However, there is no significant difference regarding adverse events between both arms.